Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gronwald
Frank Gronwald, Bedburg DE
| Patent application number | Description | Published |
|---|---|---|
| 20100172061 | Polarity Reversal Protection Unit - The polarity reversal protection unit comprises a pyrotechnic disconnecting unit, a detector device, a tripping element, a first connection element electrically connected with at least one consumer connection and a second connection element electrically connecting a supply support point with the first connection element. The pyrotechnic disconnecting unit is arranged on at least one of the connection elements. The tripping element has a first connection, electrically insulated from the connection elements, to the detector device and a second connection to one of the connection elements, so that a current flow in the tripping element causes a triggering of the pyrotechnic disconnecting unit. The triggering of the pyrotechnic disconnecting unit causes an electrical disconnection of the first and second connection elements. | 07-08-2010 |
| 20100201369 | Coated Motor Vehicle Battery Sensor Element and Method for Producing a Motor Vehicle Battery Sensor Element - The invention relates to a motor vehicle battery sensor element comprising a resistor element | 08-12-2010 |
| 20110050240 | Battery Measuring Clamp - A battery measuring clamp, comprising a battery pole clamp | 03-03-2011 |
| 20110148190 | Polarity Reversal Protection Unit for Vehicle Electric Systems of Motor Vehicles - A polarity reversal protection device for motor vehicles has a detection device ( | 06-23-2011 |
Jacek Gronwald, Szcaecin PL
| Patent application number | Description | Published |
|---|---|---|
| 20080241834 | Method for improving neoadjuvant chemotherapy - Disclosed is a method and composition for optimizing the efficiency of breast cancer neoadjuvant chemotherapy, depending on the particular constitutional genotype characteristics of the gene BRCA1 in each patient. Generally, the invention concerns a new method to improve neoadjuvant therapy depending on a particular constitutional genotype. Subject of invention allow to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly decreased clinical response to neoadjuvant chemotherapy based on taxane-derived cytostatics in breast cancer patients. | 10-02-2008 |
Jacek Gronwald, Szczecin PL
| Patent application number | Description | Published |
|---|---|---|
| 20110245095 | FAST ASSIGNMENT OF ADEQUATE CHEMOTHERAPY WITH LATINUM BASED DRUGS FOR CANCER PATIENTS BASED ON THE IDENTIFICATION OF CONSTITUTIONAL BRCAL MUTATIONS - A new method to improve therapy outcome depending on a particular constitutional genotype have been disclosed. Subject of invention allows to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly increased clinical response to chemotherapy based on platinum derived drugs in cancer patients. | 10-06-2011 |
Jacek Gronwald, Koszalin PL
| Patent application number | Description | Published |
|---|---|---|
| 20090197255 | Determining a predisposition to cancer - The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and/or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and/or breast cancer, due to germline mutation of a NBS1 gene. | 08-06-2009 |
| 20110105342 | METHOD FOR DETERMINING REDUCED PREDISPOSITION TO CANCER BASED ON GENETIC PROFILE - The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer. | 05-05-2011 |
Oliver Gronwald, Frankfurt DE
| Patent application number | Description | Published |
|---|---|---|
| 20100068593 | POLYMER ELECTROLYTE MEMBRANE WITH FUNCTIONALIZED NANOPARTICLES - The present invention relates to a polymer electrolyte membrane for fuel cells, comprising a polymer matrix of at least one basic polymer and one or more doping agents, wherein particles containing ionogenic groups and having a mean particle diameter in the nanometer range are embedded in the polymer matrix and the particles containing ionogenic groups are distributed homogeneously in the polymer matrix in a concentration of less than 50% relative to the weight of the polymer matrix, as well as to the production and use of same, especially in high-temperature fuel cells. | 03-18-2010 |
| 20110262835 | POLYMER ELECTROLYTE MEMBRANE BASED ON POLYAZOLE - Proton-conducting polymer electrolyte membrane based on a polyazole salt of an inorganic or organic acid which is doped with an acid as electrolyte, wherein the polyazole salt of the organic or inorganic acid has a lower solubility in the acid used as electrolyte than the polyazole salt of the acid used as electrolyte, a process for producing the inventive proton-conducting polymer electrolyte membrane, a membrane-electrode assembly comprising at least two electrochemically active electrodes which are separated by a polymer electrolyte membrane, wherein the polymer electrolyte membrane is a proton-conducting polymer electrolyte membrane according to the invention, and a fuel cell comprising at least one membrane-electrode assembly according to the invention. | 10-27-2011 |
Oliver Gronwald, Gottingen DE
| Patent application number | Description | Published |
|---|---|---|
| 20090075141 | HYBRID MEMBRANES, METHOD FOR PRODUCTION OF HYBRID MEMBRANES AND FUEL CELLS USING SUCH HYBRID MEMBRANES - The invention relates to hybrid membranes that are composed of an organic polymer and an inorganic polymer, a method for producing hybrid membranes, and the use of said hybrid membranes in polymer electrolyte membrane fuel cells. The inventive hybrid membranes comprise at least one alkaline organic polymer and at least one inorganic polymer. Said polymers are blended together at a molecular level. The inorganic polymer is formed from at least one precursor monomer when the membrane is produced. The disclosed membranes are characterized in that the same are provided with high absorptivity for doping agents, have a high degree of mechanical and thermal stability in both an undoped and doped state, and feature permanently high proton conductivity. | 03-19-2009 |
| 20110091788 | GAS DIFFUSION ELECTRODES COMPRISING FUNCTIONALISED NANOPARTICLES - The invention relates to a gas diffusion electrode for polymer electrolyte fuel cells having a working temperature of up to 250° C., comprising a plurality of gas-permeable electroconductive layers having at least one gas diffusion layer and one catalyst layer. The catalyst layer contains particles of an average particle diameter in the nanometer range, said particles containing ionogenic groups. The invention also relates to the production of said gas diffusion electrode and to the use of same in high-temperature polymer electrolyte membrane fuel cells. | 04-21-2011 |
Oliver Gronwald, Kurume-Shi JP
| Patent application number | Description | Published |
|---|---|---|
| 20110301230 | GENE CARRIER - Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of β-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid. | 12-08-2011 |